Automate Your Wheel Strategy on ARDX
With Tiblio's Option Bot, you can configure your own wheel strategy including ARDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARDX
- Rev/Share 1.6462
- Book/Share 0.6378
- PB 9.2668
- Debt/Equity 1.3457
- CurrentRatio 4.4129
- ROIC -0.0956
- MktCap 1415251258.0
- FreeCF/Share -0.2288
- PFCF -25.5701
- PE -25.283
- Debt/Assets 0.427
- DivYield 0
- ROE -0.3691
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ARDX | Raymond James | -- | Strong Buy | -- | $14 | Sept. 3, 2025 |
| Resumed | ARDX | H.C. Wainwright | -- | Buy | -- | $10 | June 18, 2025 |
| Downgrade | ARDX | Raymond James | Strong Buy | Outperform | -- | $11 | May 2, 2025 |
| Resumed | ARDX | Ladenburg Thalmann | -- | Buy | -- | -- | March 7, 2025 |
| Initiation | ARDX | BTIG Research | -- | Buy | -- | $14 | March 4, 2025 |
News
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
ARDX
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen's 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston.
Read More
About Ardelyx, Inc. (ARDX)
- IPO Date 2014-06-19
- Website https://www.ardelyx.com
- Industry Biotechnology
- CEO Michael G. Raab
- Employees 395
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.